Kairos Pharma ($KAPA) announced a strategic collaboration with Bayer to evaluate approaches aimed at enhancing the activity of XOFIGO® (radium Ra 223 dichloride) in patients with metastatic castration-resistant prostate cancer (mCRPC). The collaboration is focused on improving treatment outcomes by combining Kairos Pharma's research expertise with Bayer's established oncology therapy. The agreement further expands Kairos Pharma's presence in oncology research and highlights its efforts to develop innovative cancer treatment strategies. 🔑 Key Highlights 🤝 Strategic collaboration with Bayer 🩺 Focused on enhancing XOFIGO® activity 🎯 Targets metastatic castration-resistant prostate cancer (mCRPC) 🔬 Supports advancement of innovative oncology therapies 📈 Strengthens Kairos Pharma's clinical development pipeline